Transcriptional signatures indicating RB function correlate with response to CDK4/6 inhibition in endometrial cancer.
PURPOSE CDK4/6 inhibitors (CDK4/6is) are being investigated in endometrial cancer (EC) clinical trials with some patients showing a significant response. However, there are few biomarkers to predict which EC patients will respond to CDK4/6is. Current inclusion criteria include EC histology and/or lack of certain geneti...